Gout and hyperuricemia

Current Opinion in Rheumatology

Volumn 9, Issue 3, 1997, Pages 268-273

  Simkin, Peter A ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; AZATHIOPRINE; COLCHICINE; NONSTEROID ANTIINFLAMMATORY AGENT; URATE;

ANEMIA; CHRONIC KIDNEY FAILURE; GOUT; HYPERURICEMIA; KIDNEY PAPILLA NECROSIS; MYOPATHY; PRIORITY JOURNAL; REVIEW; THROMBOCYTOPENIA;

CRYSTALLIZATION; EPIDEMIOLOGIC METHODS; FORECASTING; GOUT; HUMANS; INFLAMMATION; KIDNEY; KIDNEY CALCULI; URIC ACID;

EID: 0030978349     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-199705000-00016     Document Type: Review

References (64)

1. Wise CM, Agudeto CA: Gouty arthritis and uric acid metabolism. Curr Opin Rheumatol 1996, 7:359-363.
2. Schumacher HR: Crystal-induced arthritis: an overview. Am J Med 1996, 100:463-523.
3. Emmerson BT: The management of gout. N Engl J Med 1996, 334:445-451.
4. Poor G: Crystal arthritis. Baillieres Clin Rheumatol 1995, 9:397-406.
5. Darmawan J, Lutalo SK: Gout and hyperuricaemia. Baillieres Clin Rheumatol 1995, 9:83-94.
6. Mijiyawa M: Gout in patients attending the rheumatology unit of Lome Hospital. Br J Rheumatol 1995, 34:843-846.
7. Pascual E: The diagnosis of gout and CPPD crystal arthropathy. Br J Rheumatol 1996, 35:306-308.
8. Uy JP, Nuwayhid N, Saadeh C: Unusual presentations of gout. Tips for accurate diagnosis. Postgrad Med 1996, 100:253-254,257-260,266.
9. Jaccard Y-B, Gerster J-C, Calame L: Mixed monosodium urate and calcium pyrophosphate crystal-induced arthropathy. Rev Rhum Eng Ed 1996, 63:331-335. MSU and CPPD crystals occur together rarely and then virtually always in the knee.
10. Pascual E, Jovani V: A quantitative study of the phagocytosis of urate crystals in the synovial fluid of asymptomatic joints of patients with gout. Br J Rheumatol 1995, 34:724-726.
11. Michet CJ Jr, Evans JM, Fleming KC, O'Duffy JD, Jurisson ML, Hunder GG: Common rheumatologic diseases in elderly patients. Mayo Clin Proc 1995, 70:1205-1214.
12. Fam AG, Stein J, Rubenstein J: Gouty arthritis in nodal osteoarthritis. J Rheumatol 1996, 23:684-689.
13. Holland NW, Jost D, Beutler A, Schumacher HR, Agudelo CA: Finger pad tophi in gout. J Rheumatol 1996, 23:690-692.
14. Tsai CY, Yu CL, Tsai ST: Bilateral carpal tunnel syndrome secondary to tophaceous compression of the median nerves. Scand J Rheumatol 1996, 25:107-108.
15. Wang HC, Tsai MD: Compressive ulnar neuropathy in the proximal forearm caused by a gouty tophus. Muscle Nerve 1996, 19:525-527.
16. Berman EL: Clues in the eye: ocular signs of metabolic and nutritional disorders. Geriatrics 1995, 50:34-36,43-44.
17. Blotter RH, Bruckner JD: Gouty arthropathy of the acromloclavicular joint. Am J Orthop 1995, 24:859-860.
18. Mair SD, Coogan AC, Speer KP, Hall RL: Gout as a source of sesamoid pain. Foot Ankle Int 1995, 16:613-616.
19. Chivers FS, Jaffe K, Kashlan B: Ankle pain and swelling in a 24-year-old woman. Clin Orthop 1996, 323:338-340, 343-344.
20. Bhattacharjee M, Friedman AW, Thiagarajan P: Gouty arthritis in a patient with Ivemark syndrome. South Med J 1996, 89:834-835.
21. Laversuch CJ, Bruckner FE: Development of a 'Charcot-like joint' in tophaceous gout. J R Soc Med 1995, 88:713-715.
22. Hou JW, Wang TR, Tunnessen WW Jr: Picture of the month. Glycogen storage disease type Ia (von Glerke disease) complicated by gouty arthritis and xanthomatosis. Arch Pediatr Adolesc Med 1996, 150:219-220.
23. Fred HL: Case in point. Tophaceous gout. Hosp Pract Off Ed 1995, 30:27.
24. Watts KJ, McGillis ST: Stump the experts. Gouty tophi. Dermatol Surg 1996, 22:118,194.
25. Chan T, Dunford J: Severe tophaceous gout. J Emerg Med 1996, 14:223.
26. Gerster JC, Landry M, Duvoisin B, Rappoport G: Computed tomography of the knee joint as an Indicator of intraarticular tophi in gout. Arthritis Rheum 1996, 39:1406-1409.
27. Uri DS, Dalinka MK: Imaging of arthropathies. Crystal disease. Radiol Clin North Am 1996, 34:359-374.
28. Duprez TP, Malghem J, Vande-Berg BC, Noel HM, Munting EA, Maldague BE: Gout in the cervical spine: MR pattern mimicking diskovertebral infection. AJNR Am J Neuroradiol 1996, 17:151-153.
29. Pickhardt PJ, Shapiro B: Three-phase skeletal scintigraphy in gouty arthritis: an example of potential diagnostic pitfalls in radiopharmaceutical imaging of the extremities for infection. Clin Nucl Med 1996, 21:33-39.
30. George TM, Mandell BF: Individualizing the treatment of gout. Cleve Clin J Med 1996, 63:150-155.
31. Rozenberg S, Lang T, Laatar A, Koeger AC, Orcel P, Bourgerois P: Diversity of opinions on the management of gout in France. A survey of 750 rheumatologists. Rev Rhum Engl Ed 1996, 63:255-261. French rheumatologists rely on oral colchicine atone as the primary agent for gouty arthritis but use doses substantially lower than those traditionally used in North America.
32. Pawlotsky Y: What is the optimal treatment for acute crystal-induced arthritis? Rev Rheum [Eng Ed] 1996, 63:231-233.
33. Werlen D, Gabay C, Vischer TL: Corticosteroid therapy for the treatment of acute attacks of crystal-induced arthritis: an effective alternative to nonsteroidal antiinflammatory drugs. Rev Rhum Engl Ed 1996, 63:248-254.
34. Shrestha M, Morgan DL, Moreden JM, Singh R, Nelson M, Hayes JE: Randomized double-blind comparison of the analgesic efficacy of intramuscular ketorolac and oral indomethacin in the treatment of acute gouty arthritis. Ann Emerg Med 1995, 26:682-686.
35. Chou CT, Kuo SC: The anti-inflammatory and anti-hyperuricemic effects of Chinese herbal formula danggui-nian-tong-tang on acute gouty arthritis: a comparative study with indomethacin and allopurinol. Am J Chin Med 1995, 23:261-271.
36. Rozenberg S, Roche B, Dorent R, Koeger AC, Borget C, Wrona N, Bourgeois P: Urate-oxidase for the treatment of tophaceous gout in heart transplant recipients. A report of three cases. Rev Rhum Engl Ed 1995, 62:392-394.
37. Segasothy M, Chin GL, Sia KK, Zulfigar A, Samad SA: Chronic nephrotoxicity of anti-inflammatory drugs used in the treatment of arthritis. Br J Rheumatol 1995, 34:162-165.
38. Tapal MF: Colchicine myopathy. Scand J Rheumatol 1996, 25:105-106.
39. Cummins D, Sekar M, Halil O, Banner N: Myelosuppression associated with azathioprine-allopurinol interaction after heart and lung transplantation. Transplantation 1996, 61:1661-1662. This survey exposes some of the weaknesses in our current understanding of how to adjust azathioprine dosages when allopurinol therapy becomes necessary.
40. Yale SH, Yale ES, Mann DS: Fever, rash, and angioedema after a course of allopurinol. Hosp Pract Off Ed 1996, 31:92-94.
41. Kumar A, Edward N, White Mi, Johnston PW, Catto, GR: Allopurinol, erythema multiforme, and renal insufficiency. BMJ 1996, 312:173-174.
42. Marcen R, Gallego N, Orofino L, Gamez C, Estepa MR, Sabater J, Teruel JL, Ortuno J: Impairment of tubular secretion of urate in renal transplant patients on cyclosporine. Nephron 1995, 70:307-313. Cyclosporine-induced hyperuricemia is clearly shown to be secondary to impaired tubular secretion of uric acid.
43. Ben-Hmida M, Hachicha J, Bahloul Z, Kaddour N, Kharrat M, Jarraya F, Jarraya A: Cyclosporine-induced hyperuricemia and gout in renal transplants. Transplant Proc 1995, 28:2722-2724.
44. Khatchadourian J, Preminger GM, Whitson PA, Adams-Huet B, Pak CY: Clinical and biochemical presentation of gouty diathesis: comparison of uric acid versus pure calcium stone formation. J Urol 1995, 154:1665-1669. Most gouty patients with recurrent stone formation make calcium stones and do not overexcrete uric acid.
45. Saeki A, Hosoya T, Okabe H, Saji M, Tabe A, Ichida K, Itoh K, Joh K, Sakai O: Newly discovered familial juvenile gouty nephropathy in a Japanese family. Nephron 1995, 70:359-366.
46. Many A, Hubel CA, Roberts JM: Hyperuricemia and xanthine oxidase in preeclampsia, revisted. Am J Obstet Gynecol 1996, 174:288-291.
47. Wong DF, Harris JC, Naidu S, Yokoi F, Marenco S, Dannals FR, Ravert HT, Yaster M, Evans A, Rousset O, Bryan RN, Gjedde A, Kuhar MJ, Breese GR: Dopamine transporters are markedly reduced in Lesch-Nyhan disease in vivo. Proc Natl Acad Sci U S A 1996, 93:5539-5543.
48. Ernst M, Zametkin AJ, Matochik JA, Pascualvaca D, Jons PH, Hardy K, Hankerson JG, Doudet DJ, Cohen RM: Presynaptic dopaminergic deficits in Lesch-Nyhan disease. N Engl J Med 1996, 334:1568-1572.
49. Nyhan WL, Wong DF: New approaches to understanding Lesch-Nyhan disease [editorial]. N Eng J Med 1996, 334:1602-1604.
50. Jiralerspong S, Patel PI: Regulation of the hypoxanthine phosphoribosyltransferase gene: in vitro and in vivo approaches. Proc Soc Exp Biol Med 1996, 212:116-127.
51. Nakagawa C, Mineo I, Kaido M, Fujimura H, Shimizu T, Hamaguchi T, Nakajima H, Tarui S: A new variant case of muscle phosphofructokinase deficiency, coexisting with gastric ulcer, gouty arthritis and increased hemolysis. Muscle Nerve 1995, S3:39-44. Phosphofructokinase deficiency is shown to be a cause of substantial myogenic hyperuricemia.
52. Mineo I, Tarui S: Myogenic hyperuricemia: what can we learn from metabolic myopathies? Muscle Nerve 1995, S3:75-81.
53. Eastmond CJ, Garton M, Robins S, Riddoch S: The effects of alcoholic beverages on urate metabolism in gout sufferers. Br J Rheumatol 1995, 34:756-759.
54. Vaziri ND, Freel RW, Hatch M: Effect of chronic experimental renal insufficiency on urate metabolism. J Am Soc Nephrol 1995, 6:1313-1317. Rats compensate for surgically induced renal insufficiency by increasing extrarenal excretion of urate and diminishing its biosynthesis.
55. Hachicha M, Naccache PH, McColl SR: Inflammatory microcrystals differentially regulate the secretion of macrophage inflammatory protein 1 and interleukin 8 by human neutrophils: a possible mechanism of neutrophil recruitment to sites of inflammation in synovitis. J Exp Med 1995, 182:2019-2025.
56. Roberge CJ, Gaudry M, Gilbert C, Malawista SE, de-M'edicis R, Lussier A, Poubelle PE, Naccache PH: Paradoxical effects of colchicine on the activation of human neutrophiles by chemotactic factors and inflammatory microcrystals. J Leukoc Biol 1996, 59:664-671.
57. Liote F, Prudhommeaux F, Schiltz C, Champy R, Herbelin A, Ortiz Bravo E, Bardin T: Inhibition and prevention of monosodium urate monohydrate crystal-induced acute inflammation in vivo by transforming growth factor beta I. Arthritis Rheum 1996, 39:1192-1198.
58. Chapman PT, Jamar F, Harrison AA, Schofield JB, Peters AM, Binns RM, Haskard DO: Characterization of E-selectin expression, leucocyte traffic and clinical sequelae in urate crystal-induced inflammation: an insight into gout. Br J Rheumatol 1996, 35:323-334.
59. Freedman DS, Williamson DF, Gunter EW, Byers T: Relation of serum uric acid to mortality and ischemic heart disease. Am J Epidemiol 1995, 141:637-644.
60. Vague J: The degree of masculine differentiation of obesities: a factor determining predisposition to diabetes, atherosclerosis, gout, and uric calculous disease. Obes Res 1996, 4:204-212.
61. Schmidt MI, Watson RL, Duncan BB, Metcalf P, Brancati FL, Sharrett AR, Davis CE, Heiss G: Clustering of dyslipidemia, hyperuricemia, diabetes, and hypertension and its association with fasting insulin and central and overall obesity in a general population. Atherosclerosis Risk in Communities Study Investigators. Metabolism 1996, 45:699-706. Hyperuricemia and gout are a significant part of the insulin resistance syndrome, which is marked clinically primarily by "android obesity" with an increased ratio of waste to hip girth.
62. Cigolini M, Targher G, Tonoli M, Manara F, Muggeo M, De-Sandre G: Hyperuricaemia: relationships to body fat distribution and other components of the insulin resistance syndrome in 38-year-old healthy men and women. Int J Obes Relat Metab Disord 1995, 19:92-96.
63. Lascaratos J: "Arthritis" in Byzantium (AD 324-1453): unknown information from non-medical literary sources. Ann Rheum Dis 1995, 54:951-957.
64. Rothschild BM, Heathcote GM: Characterization of gout in a skeletal population sample: presumptive diagnosis in a Micronesian population. Am J Phys Anthropol 1995, 98:519-525.